Last reviewed · How we verify
N-acetylcysteine, intralipid, heparin — Competitive Intelligence Brief
marketed
Critical Care / Supportive Care
Small molecule
Live · refreshed every 30 min
Target snapshot
N-acetylcysteine, intralipid, heparin (N-acetylcysteine, intralipid, heparin) — University Health Network, Toronto. This is a combination therapy using N-acetylcysteine as an antioxidant, intralipid as a lipid emulsion for nutritional support, and heparin as an anticoagulant.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| N-acetylcysteine, intralipid, heparin TARGET | N-acetylcysteine, intralipid, heparin | University Health Network, Toronto | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- N-acetylcysteine, intralipid, heparin CI watch — RSS
- N-acetylcysteine, intralipid, heparin CI watch — Atom
- N-acetylcysteine, intralipid, heparin CI watch — JSON
- N-acetylcysteine, intralipid, heparin alone — RSS
Cite this brief
Drug Landscape (2026). N-acetylcysteine, intralipid, heparin — Competitive Intelligence Brief. https://druglandscape.com/ci/n-acetylcysteine-intralipid-heparin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab